Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
primary open angle glaucoma
ocular hypertension
age \>18 years
You may not be if
bradycardia
obstructive pulmonary disease
hypersensitivity to the drug
Clareo Health | Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
